Home ▸ News

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

December 9, 2015

Ischemix, Inc., a clinical-stage pharmaceutical company that has developed novel compounds for cytoprotection in the kidney, heart and other organ systems, announced that a patent application covering analogs of its lead compound, CMX-2043, was recently granted approval in New Zealand. This is the first international approval for these analogs, which gained proprietary protection in the US in 2014. This new approval expands the chemical landscape established for CMX-2043 by a patent granted in 2011. Ischemix has been granted 23 international patents to date.

CMX-2043 is currently being investigated in a Phase 2 clinical trial for prevention of contrast-induced acute kidney injury and periprocedural cardiac injury in cardiac catheterization patients. In a previous, successful Phase 2 trial, CMX-2043 demonstrated the ability to significantly reduce cardiac injury in PCI patients.

“This composition of matter and method of use patent further strengthens Ischemix’ intellectual property position and advances the field of renal and cardiac cytoprotection in targeting the large, unmet medical needs for prevention of hospital-acquired acute kidney injury, including contrast-induced acute kidney injury, and for periprocedural cardiac injury” said David A. DeWahl, Jr., President and CEO of Ischemix.

Chairman and CSO of Ischemix, Reinier Beeuwkes, commented “The multi-modal mechanism of action of these compounds provides the opportunity to create effective therapeutics for diseases or conditions that afflict millions of people worldwide.”

PCT 610378 entitled “Lipoyl Compounds and Their Use For Treating Ischemic Injury” received approval by the Commissioner of Patents, Trademarks and Designs of New Zealand. This is the first international approval for US Patent No. 8,815,937 B2 entitled with the same name and issued August 26, 2014. This new patent is an extension to US Patent No. 7,928,067 B2 entitled “Compositions and Methods for Treating Ischemia and Ischemia-Reperfusion Injury” issued in April 2011.

Latest News

August, 2023

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

July 7, 2021

Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)

March 25, 2019

Novel Compound for Treatment of Traumatic Brain Injury (TBI) Demonstrates Positive Results in a Preclinical Study

April 4, 2016

Ischemix Announces Results of Its Phase 2 CARIN Trial

January 5, 2016

Ischemix, Inc. to Present at Biotech Showcase™ on January 13, 2016

December 9, 2015

Ischemix, Inc. Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound

September 30, 2015

Ischemix, Inc. Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients

August 12, 2015

Ischemix Elects Peter G. Milner, MD to Board of Directors

May 19, 2015

Safety Review Committee for CARIN Trial recommends Phase 2a study to continue as planned

March 24, 2015

Ischemix Appoints Clinical Trial Liaison

June 26, 2014

Ischemix Enrolls First Patient in Phase 2a Trial to Prevent Contrast-Induced Acute Kidney Inury

January 9, 2013

Ischemix Appoints new Chief Executive Officer

June 17, 2011

Ischemix Completes Phase 2a Clinical Trial

March 2, 2011

Ischemix Granted Composition of Matter Patent for CMX-2043

March 9, 2010

Ischemix Initiates Phase 2a Clinical Trial

August 13, 2007

Ischemix Completes Phase 1 Clinical Trial

April 5, 2007

Ischemix Initiates Clinical Development